It's Wednesday, August 26th.

Welcome to Market Fullry.

I'm Chris Hill joining me in studio.

One of the hosts of the Industry Focus Podcast, Christine Hardjus,

thanks for being here.

Thanks for having me.

So we're going to talk, we're not going to talk health care because as you and I were chatting,

you were kind enough to remind me that health care, if you're an investor and you're looking at health care, you're

basically staring at the ocean.

It is a vast, it's just, it's the Pacific Ocean, it's enormous.

So we're going to focus our discussion to biotech and

pharmaceuticals, which is still on its own a pretty big pond, but not quite the vast ocean that health care is.

That's a beautiful metaphor.

Did you like that?

I don't normally come, you know, I don't normally come equipped with with metaphor so uh a long time

listeners have heard me say that the the worst stock I ever bought was not one that went down, although I've had plenty of those.

The worst stock I ever bought was a small biotech that literally made me lose sleep.

It went up, I bought it, I ended up selling it after just a few months.

I don't know, I think I made like a 20 or 30 percent gain but of course I paid short-term

taxes on top of that but it was just one of those things where I literally woke up in the

middle of the night thinking about this company and how I didn't understand what they did.

So at least part of this episode of Market Foolery is selfishly it's going to be therapy

...